AG真人官方

Schedule 13D/A (Amendment 11) 鈥� OceanPal Inc. (OP) discloses that board member Eleftherios Papatrifon now beneficially owns 901,621 common shares (on an as-converted basis), equal to 10.59 % of the 7,611,212 outstanding. Ownership stems from 1,214 Series C and 915 Series D preferred shares, both convertible subject to a 49 % cap. The amendment is required because a change in the conversion prices of those preferred stocks reduced Papatrifon鈥檚 percentage holding; no open-market transactions are reported in the past 60 days.

The filing reiterates that the shares were acquired for investment purposes through equity awards, prior distributions from Diana Shipping, and a 2024 share-purchase agreement. As a director and Executive Committee member, Papatrifon may influence corporate strategy and continues to review further share purchases or sales. No new contracts, legal proceedings, or exhibits are included.

OceanPal Inc. (OP) 鈥� Schedule 13D/A (Amendment 36)

The amendment updates the equity position of reporting persons Semiramis Paliou, Tuscany Shipping Corp. and 4 Sweet Dreams S.A. Following an adjustment to the conversion prices of Series C and Series D preferred stock, their aggregate beneficial ownership fell to 6,091,134 common shares, or 44.45% of the 7,611,212 shares outstanding as of 18-Jul-25. The stake is held entirely through preferred stock that converts to common within 49 % ownership caps.

• Tuscany: 9,404 Series D shares 鈫� 3,982,551 common shares (34.35% of outstanding).
• 4 Sweet Dreams: 1,339 Series D + 3,640 Series C shares 鈫� 2,108,583 common shares (21.69%).
• Paliou controls both entities, so her indirect stake equals 44.45%; she holds no common shares directly.

Paliou is OceanPal鈥檚 Chair and may influence strategy, but reports the holdings are for investment purposes and may change with market conditions. A separate block of 1,200 Series E preferred shares鈥攅ach carrying up to 25,000 votes, capped at 15% of total votes鈥攔emains outstanding but is not yet convertible.

BioVie Inc. (Nasdaq: BIVI) has filed Amendment No. 1 to its Form S-1 to complete a firm-commitment public offering that will roughly double the company鈥檚 share count and strengthen short-term liquidity.

• Size & structure: 1,456,310 Units (one post-split Class A share + one 5-year warrant) or, for investors breaching the 4.99 %/9.99 % ownership caps, an equal number of Pre-funded Units (one pre-funded warrant + one warrant). Gross proceeds at the assumed $10.30 price equal 鈮� $15.0 million; net 鈮� $13.8 million after 7 % underwriting fees and estimated offering costs (exact expenses not yet disclosed). Underwriters hold a 45-day over-allotment option for 15 % additional securities.
• Pricing metrics: Warrants strike at $12.875 (125 % of the assumed offer price) and will be listed on Nasdaq as 鈥淏IVIW鈥� (listing application pending). Pre-funded warrants exercise at $0.0001 and will not be listed.
• Capitalisation impact: Shares outstanding rise from 1,860,086 (6-30-25) to 3,316,396 before any warrant exercise鈥攐r 3,534,843 if the green-shoe is exercised in full鈥攔epresenting 鈮� 78 % immediate dilution to existing holders. Potential dilution is greater when considering 960,098 legacy warrants (avg. $35.02 strike), 84,872 options (avg. $286.20 strike) and the new offering warrants (1.46 M) and banker warrants (鈮� 0.15 M).
• Reverse split executed: A 1-for-10 split became effective 7-7-25 to meet Nasdaq minimum bid requirements; all share figures reflect the split.
• Use of proceeds: 鈥淲orking capital and general corporate purposes鈥� 鈥� presumed funding of ongoing clinical trials (bezisterim/NE3107 for Alzheimer鈥檚, Parkinson鈥檚 and Long COVID; BIV201 terlipressin for ascites). No debt repayment or acquisition earmarked.
• Pipeline status: 鈥� Phase 3 AD study unblinded but undermined by cGCP violations at 15 sites, leaving an under-powered data set (81 mITT / 57 per-protocol patients). Company evaluating additional enrolment or a new Phase 3. 鈥� Phase 2b Parkinson鈥檚 study green-lit by FDA and began April 2025. 鈥� DOD-funded Phase 2 Long COVID trial (ADDRESS-LC) commenced May 2025; $13.1 M grant with $2.9 M reimbursed YTD. 鈥� BIV201 Phase 3 protocol being finalised after recent FDA guidance. Orphan Drug & Fast-Track designations remain in force.
• Litigation disclosure: Consolidated securities-fraud class action (In re BioVie Inc. Securities Litigation, D.Nev. No. 3:24-cv-00035) survived a motion to dismiss on 3-27-25 and is now in discovery; insurer deductible is $2 M.
• Risk highlights: continuing losses, need for repeated capital raises, substantial clinical and regulatory uncertainty, concentration of cash in one bank above FDIC limits, potential Nasdaq compliance issues if this offering is not deemed 鈥減ublic,鈥� and broad indemnification/blank-check preferred provisions.

The filing positions BioVie to secure modest near-term funds but materially dilutes shareholders and does not address the more costly, pivotal trials still required for commercialization. Strategic success now hinges on swift resolution of AD data integrity questions, execution of new PD/Long-COVID trials, and eventual Phase 3 initiation for BIV201.

The filing is a Form 144 notice covering a proposed insider sale of Doximity, Inc. (DOCS) common stock.

• Seller: Regina M. Benjamin (relationship to issuer not specified).
• Shares to be sold: 5,000 common shares.
• Aggregate market value: US $300,200.
• Broker: Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8th Floor, New York, NY 10004.
• Approximate sale date: 11 July 2025 on the NYSE.
• Shares outstanding: 187,826,153, making the proposed sale about 0.0027 % of outstanding shares.
• Source of shares: Acquired via stock-option exercise on 11 July 2025; paid in cash.
• Prior sales: The seller disposed of 10,000 shares on 25 June 2025 for gross proceeds of US $600,000.

No additional financial metrics, earnings figures, or strategic information are provided. The notice is routine and does not appear material to Doximity鈥檚 capital structure or operations.

UBS AG is offering $780,000 of Trigger Autocallable Contingent Yield Notes linked to NVIDIA Corporation (NVDA) common stock, maturing 15 July 2027. The notes pay a contingent quarterly coupon of 16.42% p.a. ($0.4105 per $10 note) only if NVDA鈥檚 closing price on an observation date is at or above the Coupon Barrier of $115.44 (70 % of the $164.92 Initial Level). UBS will automatically call the notes on any quarterly observation prior to maturity if NVDA closes at or above the Initial Level; investors then receive par plus the applicable coupon and the trade terminates early.

Downside exposure: If the notes are not called and the Final Level on 13 July 2027 is below the Downside Threshold ($115.44), principal is reduced 1-for-1 with NVDA鈥檚 percentage decline, potentially to zero. Principal is protected only when the Final Level remains at or above the threshold.

Key terms:

• Principal amount: $10 per note; minimum purchase 100 notes.
• Contingent Coupon Rate: 16.42% per annum, paid quarterly if conditions met.
• Automatic Call: quarterly, when NVDA 鈮� $164.92.
• Estimated initial value: $9.81, 1.9 % below the $10 issue price, reflecting fees and hedging costs.
• Credit risk: unsubordinated, unsecured debt of UBS AG, London Branch; payments depend on UBS鈥檚 solvency.
• No exchange listing; secondary market liquidity, if any, to be provided by UBS affiliates on a best-efforts basis and may be at prices well below issue price.

Risk highlights: (1) investors may lose up to 100 % of capital if NVDA falls more than 30 % and the notes are not called; (2) coupons are not guaranteed; (3) market value may be volatile and influenced by NVDA price, volatility, time to maturity, interest rates, and UBS credit spreads; (4) conflicts of interest arise because UBS structures, hedges, and makes markets in the notes. FINMA resolution powers over UBS could subject holders to bail-in or write-down in a stress scenario.

Illustrative outcomes: 鈥� Early call after the first quarter delivers 4.105 % total return. 鈥� Held to maturity with NVDA 鈮� threshold returns 8.21 % (two coupons plus principal). 鈥� Held to maturity with NVDA -33.5 % yields a 29.4 % loss despite one coupon.

Given the high coupon and equally significant downside/credit risks, the notes are suitable only for investors who are bullish-to-sideways on NVDA, comfortable with UBS credit exposure, and able to forgo dividends and liquidity.

Transaction overview: UBS AG is issuing $777,000 of unsubordinated, unsecured Trigger Autocallable Contingent Yield Notes linked to the common stock of The Kraft Heinz Company (KHC). The notes price on 11 Jul 2025, settle on 15 Jul 2025 and mature on 17 Jul 2028, unless called earlier.

• Face amount: $10 per note (minimum purchase 100 notes).
• Contingent coupon: 8.68% p.a. (paid quarterly 鈮� $0.217 per note) only when KHC closes 鈮� coupon barrier on an observation date.
• Coupon barrier / downside threshold: $19.00 (70% of initial level $27.14).
• Automatic call: Beginning 6 months after settlement and quarterly thereafter, if KHC closes 鈮� initial level ($27.14). Investors receive par + any due coupon; no further payments.
• Principal at maturity: 鈥� Par if KHC 鈮� downside threshold and notes were not called. 鈥� Par 脳 (1 + underlying return) if KHC < threshold, resulting in 1-for-1 downside exposure to 鈭�100%.
• Estimated initial value: $9.62 (UBS internal model), 3.8% below issue price due to fees/hedging costs.
• Secondary market: No listing; UBS affiliates may make markets but are not obliged to do so.

Key risks highlighted by issuer:

• Loss of up to full principal if KHC falls >30% and notes are not called.
• Coupons contingent; investors may receive few or none.
• Credit risk of UBS AG senior debt.
• Potential illiquidity and bid鈥揳sk premium in secondary trading.
• Estimated value below issue price; early resale likely below $10.

Illustrative performance scenarios: UBS shows (1) early call after two quarters producing a 4.34% total return; (2) hold to maturity with KHC 鈮� threshold producing same 4.34% total return; (3) KHC down 33.5% at maturity producing a 31.3% loss.

Use-of-proceeds & distribution: UBS Securities LLC will purchase the notes less a $0.20 per-note underwriting discount and resell to UBS Financial Services Inc.; the offering raises net proceeds of 鈮� $761,460 for UBS. Because both dealers are UBS affiliates, the deal is a FINRA 5121 conflict-of-interest offering.

Investor suitability: Product targets investors comfortable with (i) single-name equity risk, (ii) contingent income, (iii) potential illiquidity, and (iv) UBS credit exposure. Not appropriate for investors seeking principal protection, guaranteed income, or equity upside participation.

OceanPal Inc. (Nasdaq: OP) has filed Amendment No. 1 to its Form F-1 to support a firm-commitment public offering of 9,316,770 units, each comprising one common share (or, at the investor鈥檚 election, one pre-funded warrant) and one Class C warrant. The assumed public offering price is $1.61 per unit, matching the June 13 2025 Nasdaq closing price. Gross proceeds are expected to be roughly $15.0 million; net proceeds are estimated at $13.75 million (or $15.84 million if the 45-day overallotment is exercised in full). The company plans to use the cash for 鈥済eneral corporate purposes,鈥� including working capital and potential fleet expansion.

Capital structure impact: OceanPal currently has 7.5 million common shares outstanding. Immediately after the offering that figure will rise to 16.8 million shares (18.2 million if overallotment is exercised), excluding shares issuable from warrants. The Class C warrants are deeply dilutive: through price-reset and 鈥渮ero-cash鈥� exercise features they could ultimately convert into up to 139.8 million shares (160.7 million including overallotment) at no additional cash cost to investors. Management acknowledges it is 鈥渉ighly unlikely鈥� that holders will pay cash to exercise, meaning the company should not expect material warrant proceeds.

Security details: 鈥� Pre-funded warrants: $0.01 exercise price, perpetual term, 4.99%/9.99% beneficial-ownership cap. 鈥� Class C warrants: three-year life, initial strike 225 % of the offering price (~$3.62), but reset mechanisms on trading days 4 and 8 can slash the strike to as low as 50 % and 30 % of the prior-day closing price, respectively, with share quantities adjusted to keep the aggregate strike value unchanged. 鈥� A 90-day 鈥渮ero-cash鈥� option allows holders to receive twice the cash-exercise share amount without paying the strike price.

Nasdaq status: OceanPal fell out of bid-price compliance on April 17 2025 but regained compliance on June 30 2025 after ten consecutive trading days above $1.00.

Fleet overview: The company owns three vessels鈥攖wo Panamax dry-bulk carriers (149,916 dwt combined, average age 20.3 years) and one MR2 product tanker (49,999 dwt, age 16.3 years)鈥攁ll held through separate subsidiaries. A non-core vessel (M/V Protefs) was sold on June 12 2025 for $7.0 million.

Risk highlights: 鈥� Potential issuance of up to 160.7 million shares via warrants could cause severe dilution and threaten continued Nasdaq listing. 鈥� OceanPal operates a very small, elderly fleet in highly volatile dry-bulk and product-tanker markets, exposing it to rate swings, regulatory costs (e.g., IMO ballast-water rules) and heightened operating risk. 鈥� The company remains classified as an emerging growth company and a foreign private issuer, allowing reduced disclosure but limiting investor protections. 鈥� There is no trading market for the warrants, reducing liquidity for unit investors.

Key takeaways: The offering provides short-term liquidity and restores a cushion above Nasdaq鈥檚 minimum equity requirements, yet the warrant structure introduces extraordinary dilution risk. Investors should weigh the modest $13-16 million cash infusion against the prospect of a share count that could expand more than ten-fold.

OceanPal Inc. (Nasdaq: OP) has filed a Form F-1 for a firm-commitment public offering of 9,316,770 Units, each comprised of one Common Share (or one Pre-Funded Warrant) and one Class C Warrant. The assumed public offering price is $1.61 per Unit, based on the June 13, 2025 Nasdaq close. Class C Warrants carry an initial exercise price equal to 225% of the final offering price (鈮� $3.6225 at the assumed price) and are subject to two automatic downward resets on the 4th and 8th trading days after issuance. These resets can lower the exercise price to as little as 50% and 30%, respectively, of the pre-pricing closing price while proportionally increasing the number of shares issuable so that the aggregate exercise value remains constant.

Holders may elect a zero-cash exercise during the first 90 days, potentially doubling share delivery without additional consideration. At the assumed pricing, a single Warrant could become exercisable for up to 15 Common Shares after both resets under the zero-cash option. Consequently, the filing registers up to 139,751,550 Common Shares underlying Warrants (or 160,714,275 including over-allotment Warrants), indicating substantial potential dilution. The company cautions it is "highly unlikely" to receive cash proceeds from Warrant exercises.

The Pre-Funded Warrants, priced $0.01 below the Unit price and exercisable at $0.01 per share, provide an alternative for purchasers seeking to cap post-offering ownership at 4.99% (optionally 9.99%). OceanPal qualifies as an Emerging Growth Company and intends to utilize reduced disclosure requirements. The Warrants and Pre-Funded Warrants will not be listed on any exchange, limiting liquidity. No other financial results or use-of-proceeds details are provided in this preliminary prospectus.